NANOSONICS LIMITED — Capital/Financing Update 2012

May 3, 2012

==> picture [287 x 84] intentionally omitted <==

4 May 2012

Company Announcements Office Australian Securities Exchange

Nanosonics raises $15.5 million from Institutional and Sophisticated Investors

Nanosonics Limited (ASX: NAN) is pleased to announce the successful placement of 29.25 million shares to raise $15.5 million from institutional and sophisticated investors. The placement was made at $0.53 cents.

The placement was led by fund manager Allan Gray (formerly Orbis Investment Management (Australia)) which has committed $10.6 Million to the placement. Shaw Corporate Finance is acting as participating broker to the placement.

The Company’s unique Trophon EPR[®] system sets the new “gold standard” for hospitals and medical centres to dramatically improve infection control standards, workflow and traceability while reducing the likelihood of healthcare acquired infections from the use of intra-cavity ultrasound probes.

Since its launch, Trophon EPR has been steadily building a strong base of users in Australia, New Zealand, the USA, Canada and Europe.

Trophon EPR, which is exclusively distributed by GE Healthcare in the US and Canada, has been adopted by a number of high profile US healthcare institutions of medical excellence. Further, the US military and the large Veterans Affairs hospital system have purchased significant numbers of Trophon EPR since its launch, less than a year ago. Nanosonics continues to drive the commercialisation of the Trophon EPR in each of the key markets.

Following settlement of the placement, the Company will have a cash balance in excess of $20 million, ensuring that it is strongly positioned to drive the commercialisation of the Trophon EPR and continue developing its valuable new product pipeline.

The funds raised by the placement will be used towards:

• Working capital to support sales, distributor and marketing programs

• Investment in expanding direct sales resources in key markets

• Continued investment in development of promising additional products utilising the Company’s proprietary technology

• Scaling-up manufacturing

Nanosonics Limited ABN 11 095 076 896 Unit 24 566 Gardeners Road Alexandria NSW 2015 Australia Tel: +61 2 8063 1600 Fax: +61 2 9317 5010 Email: info@nanosonics.com.au w: www.nanosonics.com.au

Share Purchase Plan

It is intended that a Share Purchase Plan (SSP) will be offered to enabling Nanosonics’ shareholders on its register as at 3 May 2012 to subscribe for additional shares at $0.53 cents. The full details of the SSP will be released next week.

In accordance with ASX Listing Rule 3.10.5 attached is the Appendix 3B relating to the placement.

Secondary Trading Exemption

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A. By the Company giving this notice, a sale of the Securities noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

• a) The Company issued the Securities without disclosure to investors under Part 6D.2 of the Act;

• b) as at 4 May 2012 the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and

• c) as at 4 May 2012 there is no information:

• i. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and

• ii. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:

  • A. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or

  • B. the rights and liabilities attaching to the Securities.

Nanosonics Limited

McGregor Grant Company Secretary